Impact of CES1 Genotype on Remimazolam
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-70
SponsorKorea University Guro Hospital
About this trial
Remimazolam is primarily metabolized via CES1, and other drugs that are commonly metabolized by CES1 are known to have their pharmacokinetics and clinical effects affected by genetic polymorphisms in CES1.
The goal of this observational study is to investigate the impact of the CES1 genotype on the pharmacokinetics, safety, and efficacy of remimazolam in patients undergoing elective surgery.
Eligibility criteria
Qualifiers
American Society of Anesthesiologists (ASA) physical status 1 or 2
Age 19-70 years
Elective surgery
Disqualifiers
Concomitant regional anesthesia
Uncontrolled hypertension (systolic blood pressure >180 mmHg)
Uncontrolled diabetes mellitus (HbA1c >9.0%)
Aspartate transaminase (AST), Alanine transferase (ALT), Total bilirubin > more than 2 times the normal upper limit
Trial design
Treatments tested in this trial
- Remimazolam besylate
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov